Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound

PHASE4TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions
Pressure Injury Stage 2
Interventions
DRUG

Fespixon Cream

"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"

Trial Locations (3)

801

Kaohsiung Municipal Ta-Tung Hospital(Managed by Kaohsiung Medical University Chung-Ho Memorial Hospital), Kaohsiung City

10675

Taipei Medical University WanFang Hospital, Taipei

80756

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Oneness Biotech Co., Ltd.

INDUSTRY

lead

Taipei Medical University WanFang Hospital

OTHER